Objectives: The aims and objectives of this systematic review are to investigate the different theories underlining major depression and suicide while exploring the correlation between BDNF, major depression and suicide. Method: Literature was researched through the University of Malta research platform and statistical reports published by the Maltese National Statistics Office, Eurostat and World Health Organisation were consulted. Depression: Low blood BDNF levels have been identified to occur in major depression which normalise during remission. Additionally, since BDNF is associated with increased neural plasticity and survival and decreased atrophy, exposure to chronic stress was identified to decrease BDNF levels and reverse such traits in laboratory rats. Single nucleotide polymorphism Val66Met on the BDNF gene has been identified to be responsible for decreased activity-dependent secretion of BDNF and resultantly increased depressive features. Sertraline administration in human subjects and laboratory rats has been also identified to have a neurogenic effect on serotonergic and BDNF neurons; increasing their expression. Suicide: Despite that suicide is commonly associated as part of the symptomatology of psychiatric disorders, in light that children of suicide attempters are six times more susceptible to attempt suicide than children of non-suicide attempters; recent research considered suicide as an independent phenomenon with a high percentage of heritability. Higher concentrations of cholecystokinin receptors and cholecystokinin B receptors have been reported in individuals who died by suicide. Conclusion: Large randomised replicated research looking into BDNF, major depression and suicide is still absent. Further research is necessary to validate the reported findings.
Introduction
Major Depressive Disorder (MDD) is the commonest major psychiatric illness globally with an estimated 350 million effected individuals across all age groups [1] . MDD is the major cause of disability and is the major contributor to the overall burden of disease globally (Davies & Craig, 2009 ; Abramets et al., 2015; WHO, 2016) . Untreated depressive episodes may last between six to 24 months with individuals experiencing first-onset episodes exhibiting 50% -60% chance of experiencing a second one. Additionally, around 9% of those diagnosed with MDD also described psychotic features [2] [3] . Depression is strongly correlated to suicide; 80% of individuals who commit suicide suffer from depression while 15% of those diagnose with MDD commit suicide [4] .
Suicide is a major cause of death within the European Union (EU); in 2011, 60,000 individuals committed suicide [5] . Statistically suicide accounts for 17.6% of all deaths among young adults in high-income countries, ranking as the second leading cause of death within this age group following road traffic accidents both in the EU and globally [6] [7] . Suicide is the second leading cause of death amongst 15 -29-year olds [1] . In the United Kingdom, 5000 individuals die by suicide each year and it is estimated that ~450 involve overdose with antidepressants [2] . Malta has a rate of 5.1 suicides per 100,000 inhabitants [8] .
Pathophysiological Theories of Depression

Monoamine Hypothesis
The monoamine hypothesis describes that MDD is a result of a dysfunctional monoamine neurotransmitter system, particularly; serotonin, noradrenaline, adrenaline and dopamine, resulting in decreased extracellular monoamines concentrations and neurotransmission (Ruhe et al., 2007 ; Jentsch et al., 2015) .
The decrease in monoamine neurotransmission possibly results from three factors; too little neurotransmitters released by presynaptic neurons, rapidly reabsorbed/degraded neurotransmitters or a decrease in postsynaptic receptors [2] . Decreased monoamine metabolite concentrations have been also identified in the Cerebrospinal Fluid (CSF), blood, urine and post-mortem brain tissue of individuals diagnosed with MDD (Jentsch et al., 2015) . Research looking into this pathophysiological theory mimicked monoamine neurotransmitter depletion by tryptophan, phenylalanine and tyrosine depletion (precursors) by removing them from the diet or blocking their synthesis; this "depletion" induced depressive symptoms. Depressive symptoms were noticed in individuals with a history of MDD and non-depressed relatives of MDD individuals but not in healthy in- 
Hypothalamic-Pituitary-Adrenal Axis
Activation of neuroendocrine systems is a primary physiological response to stress, principally by the Hypothalamic-Pituitary-Adrenal (HPA) axis. Emotional stimuli reach the amygdala and forebrain which stimulate the HPA axis. The amygdala stimulates the hypothalamus which in turn excites the HPA axis which by increasing blood cortisol concentrations acts on a positive feedback mechanism to further stimulate the amygdala. Over-excitation of the HPA axis is inhibited with a negative feedback mechanism by the hippocampus which 
Inflammatory Hypothesis
The inflammatory hypothesis suggests that inflammatory changes, primarily; increased pro-inflammatory cytokine, decreased anti-inflammatory cytokine concentrations and activation of immune cells to be partially related to the onset of MDD. Supporting such hypothesis are increased levels of interleukin-1, interleukin-6 and decreased levels of anti-inflammatory cytokines (interleukin-4 and interleukin-10), recognising pro-inflammatory markers to cause depressive-like symptoms. Pro-inflammatory cytokines are also activated in other disorders not necessarily related to depression and not causing depression; eliminating the inflammatory hypothesis as a prime causative factor of MDD (Jentsch et al., 2015). 
Treatment
BDNF
BDNF is the commonest NT regulating neural plasticity, particularly in the lim- 
Depression
The BDNF gene has several polymorphic markers, amongst which a single nucleotide polymorphism (SNP) at nucleotide 196G/A resulting in the substitution of a valine into a methionine nucleotide at codon 66 (Val66Met). This SNP effects intracellular processing and secretion, decreased activity-dependent secre- High baseline serum BDNF and early improvement to treatment predicted successful outcome while initial increase in serum BDNF during treatment was considered unsuccessful. Diverging from previous research, more severe depressive symptoms were reported by participants with high serum BDNF; the authors argued that this resulted from rigorous statistical procedures which excluded confounding factors with regards to age, gender, education and illness. However, issues like smoking and quality of sleep which alter serum BDNF were not accounted for. The authors concluded that pronounced serum BDNF in severe MDD due to Chronic Mild Stress (CMS) prior to treatment is probably a compensatory mechanism. Supporting this hypothesis is the fact that serum BDNF was not reported to increase upon remission of depressive symptoms (Mikoteit et al., 2014).
In another study serum BDNF levels were not reported to stabilise following antidepressant therapy. This deviation was associated to the fact that unlike Since BDNF crosses the blood brain barrier it is assumed that blood BDNF levels equal brain BDNF; for this reason, several studies tried to clarify the correlation between BDNF levels, MDD, ethnical groups, age and gender. However, no significant results have been reported (Kreinin et al., 2015) . Research demonstrated a discrepancy in the lifetime prevalence of MDD between men and women of 11% and 21% respectively, indicating a correlation between gender, BDNF levels and MDD. Kreinin et al. (2015) , investigated the diagnostic value of BDNF as a potential marker for MDD but no significance was reported.
Stratified analysis correlating BDNF levels and depression severity demonstrated insignificant differences in mild depression and significant differences in severely depressed participants. Upon gender discrimination, a significant positive correlation between blood BDNF and MDD severity has been shown in fe- BDNF infusions and hippocampal astrocytic plasticity in rats exhibiting depressive-like symptoms. Following three weeks of CMS, sucrose consumption, total travel distance and velocity significantly decreased when compared to the control group; implying that the group exposed to CMS exhibited depressive symptoms. The cohort was divided into three groups; control + saline, CMS + saline and CMS + BDNF. Upon analysis, significant differences following BDNF treatment were identified. Depressive symptoms were significantly increased in the CMS + saline when compared to the control + saline group. Depressive symptoms in the CMS + BDNF were significantly decreased when compared to the CMS + saline group, while no significant differences were identified between the control + saline and CMS + BDNF groups. The same pattern was also ob- Since BDNF regulates neuronal survival and synaptic plasticity, it may also have a role in white matter integrity and MDD in the elderly. Alexopoulos et al.
(2010), investigated the effect Val66Met SNP has on remission from late-life MDD and explored the correlation with microstructural white matter abnormalities. The study reported that like younger individuals, depressed elderly Caucasian individuals with BDNF met allele were more likely to achieve remission than BDNF val/val homozygotes after 12 weeks of treatment. Additionally, microstructural abnormalities in the corpus callosum, left superior corona radiata and right inferior longitudinal fasciculus were associated with lower remission rates, but no correlation has been found between the studied BDNF allele, elderly MDD and white matter abnormalities (Alexopoulos et al., 2010).
Depression is also common after stroke, both psychosocial and biological factors are important in the development of post-stroke depression (PSD) (Kim et al., 2013). BDNF expression is regulated by epigenetic chromatin remodelling in the gene promoter regions. Previous depression was described in 15% of the participants. The PSD group was more likely to have had a history of depression when compared to those without PSD. Results showed that BDNF promoter methylation at CpG site 6 exhibited higher incidence of prevalent, persistent and incident PSD while methylation at CpG sites 1, 2 and 4 were more associated with incident PSD. Principally, the higher the methylation of BDNF promoter gene the higher the risk of prevalent, persistent and incident PSD with signifi- 1) BDNF relies on activity-dependant release mechanism which is decreased with higher methylation (thus in stroke and increased methylation, BDNF is decreased).
2) Since BDNF has antidepressant activity, lower BDNF secretion after stroke increases depressive symptoms.
(Kim et al., 2013) Another study investigating PSD investigated the independent and interactive association of serotonin transporter, serotonin 2a receptor and BDNF genes in PSD (Kim et al., 2012). A total of 276 participants with a mean age of 64.3 years were recruited and interviewed at 12 days post-stroke. 10.5% were diagnosed with MDD, 17.4% with minor depression, 5.4% reported previous depression and 27.9% were categorised as having PSD. The PSD group was more likely to be older, have experienced past depressive episodes and/or stroke and more likely to have had an anterior stroke. Genotyping demonstrated that participants with any form of depression had significantly higher short allele levels in the promoter region of the serotonin transporter, 1438 A allele in the serotonin receptor The s/s allele in the serotonin transporter and the BDNF met/met genotypes were significantly associated with any depression and only the 1438 A/A serotonin receptor gene was linked to MDD. Serotonin transporter and receptor distribution were not independent; however, no significant interactive effects of genes have been identified with stroke location. This is the only study found investigating the correlation between serotonin receptor 2a polymorphisms and PSD (Kim et al., 2012). Asserting the study's reliability is the fact that despite the small number of participants recruited, depression was ascertained prior recruitment using a structured diagnostic interview based on the Diagnostic Statistical Manual IV (DSM-IV) at a similar time-point in all participants.
The role of epigenetics in the occurrence of depression and suicide has also been researched and a systematic review conducted by Lockwood et al. BDNF gene methylation was also found to be significantly associated with MDD and suicidal ideation. BDNF methylation was more pronounced in individuals with MDD than participants with manic or bipolar disorder. The study also reported that lithium carbonate and sodium valproate decrease the level of BDNF methylation, however statistical significance was not reached (Dell; Osso et al., 2014) . In this review the authors acknowledged that the studies utilised were all preliminary studies with small samples, however most studies agreed with each other, confirming the correlation between epigenetic alterations, MDD and suicide (Lockwood et al., 2015).
Suicide
Suicidal behaviour is generally associated as part of the symptomatology of a psychiatric disorder. Despite that it is strongly associated with psychiatric co-morbidities, recent research also considered suicide as an independent phe- Higher Cholecystokinin (CCK) receptors in frontal cortex and Cholecystokinin B Receptor (CCKBR) in the cerebellum, pre-frontal cortex and cingulate gyrus have been reported in individuals who died by suicide. Considering these facts, a study tried to identify any possible correlation between SNPs in the BDNF, CCK and CCKBR genes and suicide. From the BDNF gene, five SNPs were significantly correlated with attempted suicide, however no association was identified between Val66Met allele and attempted suicide; which replicated results from other studies which further elaborated that the Val66Met allele is significantly associated with MDD but not with attempted suicide (Neves et al., 2011). CCK and CCKBR have been previously studied and relationship with a number of psychiatric disorders has been established. 12 CCKBR SNPs were significantly associated with attempted suicide. No CCK SNPs were found to be associated with suicide. Despite significant associations of the respective genes with attempted suicide, none of the associations have evidence supporting their association with suicidality in genome-wide association studies.
Low serum BDNF levels are generally described in MDD patients; however research reports conflicting results with regards serum BDNF levels in completed suicides. A study conducted amongst 281 participants (84 attempted suicides, 104 psychiatric controls and 93 community controls) reported no significant differences amongst the different groups after adjustment to age, sex, age, psychiatric co-morbidity and smoking between attempted suicide and serum Previously conducted studies demonstrated that the BDNF Val66Met SNP is not only correlated to MDD, but is also associated to suicidal behaviour in MDD, suicide attempts in bipolar disorder and schizophrenia (Ratta-apha et al., 2013) . A study that attempted to replicate potential associations between SNPs on the BDNF gene and suicide demonstrated that when compared to the BDNF val allele, the BDNF met allele was found to be associated with suicide attempts in Asian populations but not with completed suicide. No significant differences were reported between completed suicide and control groups in BDNF val and BDNF met allele occurrence (Pregelj et al., 2011; Ratta-apha et al., 2013 ). The authors speculate that this discrepancy may result due to the pathogenesis of completed suicides being more complex than that of attempted suicides.
The BDNF met allele was found to have no correlation to suicide attempts with regards to age, sex, ethnicity, marital status, schooling years, familial psychiatric history and substance misuse. However, the presence of the BDNF met allele was correlated with high lethality attempted suicides. As predicted, male gender was also independently and significantly associated with lethality of attempted suicide. Additionally, suicide lethality has also been correlated with decreased sero- 
Discussion
The increased evidence of different processes undergoing in programmed cell death to develop pharmacological agents to treat pathological neuronal death, is now better defined by the widely held assumption that neuronal death is the primary culprit in the pathophysiology of these diseases. Increasing evidence suggests that neuronal and synaptic dysfunctions precede neuronal degeneration Nonetheless, independent of psychiatric diagnoses, abnormal BDNF function has been associated with elevated suicidality and possibly that treatment-induced improvement in BDNF system prevents or decreases suicidal behaviour independently of improvement in psychiatric symptomatology [9] . Studies utilising laboratory rats demonstrated that BDNF produced antidepressant results in depressed rats when; delivered as a continuous high-dose infusion to the mid-brain, 
Conclusion
The absolute aetiology of MDD is unknown; however tenets for further research have been clearly identified. Influencing genetic, environmental and cultural factors leading towards the development of MDD and suicide have been identified but further research is necessary to identify how these interact together and cause the resulting pathophysiology and behavioural changes in psychiatric disease.
Dedication
Dedicated to J.S., a colleague but most of all a loyal friend who unfortunately died due to depression. May the experience of your suffering remind us that as professionals we are not immune to mental health issues and help us to better assist those in need. Carved in the literature and concealed with an immortal veil of surrealism, your memory shall never be forgotten.
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